Gilead poached Amgen R&D executives

CompilationFan Dongdong

According to the latest news, Gilead Sciences has hired Amgen R&D executive Flavius ​​Martin to run Gilead’s R&D department.

After joining, Martin will serve as Gilead’s Vice President of R&D and will report directly to Gilead’s Chairman and CEO Daniel O'Day.

Regarding this personnel change, O'Day said, “Flavius ​​has decades of experience in early drug discovery research and identification of promising therapeutic candidates.

In 2017, Gilead announced that it would acquire Kite Pharma, an anti-cancer drug manufacturing company, at a price of US$180 per share and spend more than US$10 billion, expanding the research and development line of tumor therapy, and spending billions of US dollars to strengthen cooperation and anchoring.

In addition to the field of oncology, Gilead did not delay its original virology business.

Reference source: Gilead poaches Amgen exec Flavius ​​Martin to run its R&D as 30-year veteran Bill Lee retires